News | September 03, 2009

Study Finds Fewer Heart Attacks With Procoralan in Angina Patients

September 3, 2009 – Important new findings in patients with angina participating in the BEAUTIFUL study show that there is a 42 percent reduction in heart attack with Procoralan (ivabradine), as presented today at the European Society of Cardiology (ESC) Congress.

This benefit was particularly marked in patients with a resting heart rate – greater than or equal to 70 beats per minute (bpm) – where Procoralan cut the risk of hospitalization for heart attack by nearly three quarters and the rate of coronary revascularization by more than half.

These findings set Procoralan apart as an antianginal agent documented to be able to reduce major cardiovascular events in angina patients. The drug maker said these impressive efficacy results stem from a subgroup analysis of patients in the BEAUTIFUL study with limiting angina. Angina is the most common manifestation of coronary artery disease (CAD) and can have a profound impact on patients' quality of life, as well as adversely affecting prognosis. In this analysis, Procoralan reduced the primary endpoint - a combination of cardiovascular death, myocardial infarction (MI) and heart failure - in all angina patients by 24 percent with an improvement on all parameters. Hospitalizations for fatal or non-fatal MI were also reduced by 42 percent with Procoralan. This benefit was even more striking in angina patients with a heart rate (greater than or equal to) 70 bpm, where the risk of MI was cut by 73 percent. The need for coronary revascularisation was also reduced with Procoralan treatment, decreasing by 30 percent in all angina patients and 59 percent in those with a heart rate greater than or equal to 70 bpm.

A total of 1,507 patients with angina were included in this BEAUTIFUL subgroup analysis and half of them had a heart rate more than 70 bpm at baseline. Nearly all patients were receiving conventional treatment aimed at protecting against cardiovascular events, with approximately nine out of every 10 patients on beta-blockers.

Previously released results from the BEAUTIFUL study have already shown in 10,917 patients with CAD and associated left ventricular dysfunction, that Procoralan reduces both fatal and non-fatal heart attack by 36 percent and need for revascularisation by 30 percent in coronary patients with a heart rate higher than 70 bpm.

Angina is a presenting symptom in half of all coronary patients and the presence of angina can adversely affect their prognosis. Procoralan is one of the most important advances in stable angina treatment in the last two decades. The antianginal and anti-ischaemic efficacy of Procoralan has been very well documented in monotherapy and in combination with beta-blocker. In angina patients already receiving beta-blockers, the addition of Procoralan significantly prolongs total exercise duration.

"These new results on the prevention of cardiovascular events with Procoralan in angina patients, further reinforce the place of Procoralan as a step further in the management of angina patients," said professor K. Fox, cochairman of the BEAUTIFUL Executive Committee study.

The study is funded by Servier, one of France's leading independent pharmaceutical companies. The name of the drug depends on the country – ivabradine is available as Procoralan, Coralan, Coraxan, or Corlentor.

For more information: www.servier.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init